Members |
targetComponentId |
Lymphoma morphology |
Malignant lymphoma |
nodalt/systemisk lymfoplasmacytært B-celle-lymfom med hudinvolvering |
Malignant lymphoma - lymphoplasmacytic |
lymfoproliferativ sygdom |
Lymphoproliferation of uncertain behavior (morphologic abnormality) |
Lymphosarcoma cell leukemia |
Lymphoid leukaemia |
Lymphosarcoma cell leukemia |
Lymphoid leukaemia |
Lymphosarcoma of extranodal AND/OR solid organ site |
Non-Hodgkin's lymphoma (clinical) |
Lymphosarcoma of intra-abdominal lymph nodes |
Mixed cell type lymphosarcoma of intra-abdominal lymph nodes |
Lymphosarcoma of intrapelvic lymph nodes |
Non-Hodgkin's lymphoma (clinical) |
Lymphosarcoma of intrathoracic lymph nodes |
Mixed cell type lymphosarcoma of intrathoracic lymph nodes |
Lymphosarcoma of lymph nodes of axilla AND/OR upper limb |
Non-Hodgkin's lymphoma (clinical) |
Lymphosarcoma of lymph nodes of head, face AND/OR neck (disorder) |
Non-Hodgkin's lymphoma (clinical) |
Lymphosarcoma of lymph nodes of inguinal region AND/OR lower limb |
Non-Hodgkin's lymphoma (clinical) |
Lymphosarcoma of lymph nodes of multiple sites |
Malignant lymphoma of lymph nodes |
Lymphosarcoma of spleen |
Non-Hodgkin's lymphoma (clinical) |
Lyophilized powder |
A solid dose form consisting of one or more particulate solids of varying degrees of fineness. |
lyofiliseret pulver til injicerbar liposomal suspension |
Powder for suspension for injection |
Lyophilized powder for conventional release solution for infusion |
Powder for conventional release solution for infusion (dose form) |
Lyophilized powder for conventional release solution for infusion and/or injection |
Powder for conventional release solution for infusion and/or injection (dose form) |
lyofiliseret pulver til injicerbar opløsning |
Powder for solution for injection |
lyofiliseret pulver til injicerbar suspension |
Powder for suspension for injection |
lyofiliseret pulver til injicerbar liposomal depotsuspension |
Powder for prolonged-release suspension for injection (dose form) |
allergi over for lypressin |
Allergy to antidiuretic hormone |
Lysis of adhesions of abdomen |
Lysis of adhesions of peritoneum |
lytisk morfologisk forandring af knoglevæv ved røntgenundersøgelse |
Lytic lesion of bone on plain X-ray (finding) |
Lückenschadel |
Craniolacunia |
M+nage E trois |
Ménage à trois |
M0-stadium |
American Joint Committee on Cancer cM0 (qualifier value) |
M1 (IV): Fjernmetastase |
American Joint Committee on Cancer cM1 (qualifier value) |
M1 (IVB): Fjernmetastase |
American Joint Committee on Cancer cM1 (qualifier value) |
M1-stadium |
American Joint Committee on Cancer cM1 (qualifier value) |
M1: Fjernmetastasering [inklusive metastasering til ipsilaterale supraklavikulære lymfeknuder] |
American Joint Committee on Cancer cM1 (qualifier value) |
M1: fjernmetastase inklusive separat(e) tumornodulus(noduli) i en anden lobus ipsilateralt eller kontralateralt |
American Joint Committee on Cancer cM1 (qualifier value) |
M1a (III): GTT med spredning til lungerne med eller uden involvering af tractus genitalis |
American Joint Committee on Cancer cM1a (qualifier value) |
M1a (IIIA): GTT med spredning til lungerne med eller uden involvering af tractus genitalis uden risikofaktorer |
American Joint Committee on Cancer cM1a (qualifier value) |
M1a (IIIB): GTT med spredning til lungerne med eller uden involvering af tractus genitalis med én risikofaktor |
American Joint Committee on Cancer cM1a (qualifier value) |
M1a (IIIC): GTT med spredning til lungerne med eller uden involvering af tractus genitalis med to risikofaktorer |
American Joint Committee on Cancer cM1a (qualifier value) |
M1a: Metastasering til ikke-regionale lymfeknuder eller lunger |
American Joint Committee on Cancer cM1a (qualifier value) |
M1a: metastasering til ikke-regionale lymfeknuder |
American Joint Committee on Cancer cM1a (qualifier value) |
M1b (IV): Alle øvrige metastaselokalisationer |
American Joint Committee on Cancer cM1b (qualifier value) |
M1b (IVA): Alle øvrige metastaselokalisationer uden risikofaktorer |
American Joint Committee on Cancer cM1b (qualifier value) |
M1b (IVB): Alle øvrige metastaselokalisationer med en risikofaktor |
American Joint Committee on Cancer cM1b (qualifier value) |
M1b (IVC): Alle øvrige metastaselokalisationer med to risikofaktorer |
American Joint Committee on Cancer cM1b (qualifier value) |
M1b: Knogle(r) |
American Joint Committee on Cancer cM1b (qualifier value) |
M1b: Fjernmetastase til andet end ikke-regionale lymfeknuder og lunger |
American Joint Committee on Cancer cM1b (qualifier value) |
M1c: Anden/andre lokalisation(er) |
American Joint Committee on Cancer cM1c (qualifier value) |
MCH - NOS |
Mean corpuscular hemoglobin determination |
MV |
megavolt (qualifier value) |
MYH9 macrothrombocytopenia syndrome |
MYH9-related disease (MYH9-RD) is an inherited giant platelet disorder with a complex phenotype characterized by congenital thrombocytopenia and possible subsequent manifestations of sensorineural hearing loss, presenile cataracts, elevation of liver enzymes, and/or progressive nephropathy often leading to end-stage renal disease (ESRD). Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly and Sebastian syndrome, previously described as distinct disorders, represent some of the different clinical presentations of MYH9-RD. |
Machine tool operator |
Machine-tool operator (general) |
Mackerel - dietary |
Mackerel (substance) |
Macrocytic anaemia of unspecified cause |
Macrocytic anemia |
Macrocytic anemia of unspecified cause |
Macrocytic anemia |
overdosis af macrolid |
Macrolide antibacterial overdose (disorder) |
Madleners sterilisationsoperation |
Ligation and crushing of bilateral fallopian tubes (procedure) |
mafenidacetat 5 % pulver |
Product containing only mafenide (medicinal product) |
Mafenide acetate 85mg/g conventional release cutaneous cream |
Product containing precisely mafenide (as mafenide acetate) 85 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
mafenidacetat 85 mg/g creme |
Product containing precisely mafenide (as mafenide acetate) 85 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
Magaldrate 800mg/5mL suspension |
Product containing precisely magaldrate 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
magnesiumaspartathydrochlorid |
Product containing magnesium aspartate (medicinal product) |
magnesiumklorid 200 mg/ml injektionsvæske, opløsning , ampul |
Product containing only magnesium chloride in parenteral dose form (medicinal product form) |
magnesiumcitrat 17,7 g/brev pulver |
Product containing only magnesium citrate (medicinal product) |
magnesiumsalicylat 467 mg kapselformet tablet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
Magnesium salicylate 467mg conventional release oral tablet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
magnesiumsalicylat 500 mg tablet kapselformet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
Magnesium salicylate 500mg conventional release oral tablet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
magnesiumtrisilicat + belladonna 0,15 mg tablet |
Belladonna alkaloid and magnesium trisilicate only product |
magnesiumbaseret antacidum |
Magnesium compound |
Magnetic resonance imaging contrast media |
Magnetic resonance imaging contrast media (substance) |
kontraststof til MR-scanning |
Magnetic resonance imaging contrast media (substance) |
Mail/message distributor NOS |
Mail distribution clerk |
Mail/message distributor NOS |
Mail distribution clerk |
Maintenance of prosthesis in organ NOC |
Attention to device (procedure) |
Maintenance technician NOS |
Maintenance technician |
Maintenance technician NOS |
Maintenance technician |
Major amblyoscope |
Major amblyoscope (physical object) |
Major depressive disorder clinical management plan |
Major depressive disorder clinical management plan |
Major puerperal infektion |
Postnatal infection |
større puerperal infektion, ikke nærmere specificeret |
Postnatal infection |
Major puerperal infection NOS |
Postnatal infection |
større puerperal infektion, ikke nærmere specificeret, uspecificeret |
Postnatal infection |
fund vedr. store spytkirtler udtrykt ved TNM-systemet |
American Joint Committee on Cancer allowable value |
Stor torakotomi med åben intrapleural pneumonolyse |
Therapeutic pneumothorax (procedure) |
Foretager obskøne telefonopringninger |
Telephone scatologia |
malariaantistof |
Plasmodium antibody |
malathion 1 % cremeshampoo |
Malathion 10 mg/mL shampoo |
erektionsforstyrrelse hos mand/dreng |
Erectile dysfunction |
patients mandlige forlovede |
Male fiance |
Male genital infection NOS |
Male genital infection |
Male genital organ disease NOS |
Disorder of male genital organ (disorder) |
Male genital organ disease NOS |
Disorder of male genital organ (disorder) |
Male genital organ disease NOS |
Disorder of male genital organ (disorder) |
Male genital organ operations NOS |
Operation on male genital system |
Male genital organ operations NOS |
Operation on male genital system |
Mandlig bækkenperitonit |
Pelvic peritonitis |
Male sex hormones NOS |
Male sex hormones - serum measurement |
Male sex hormones NOS |
Male sex hormones - serum measurement |
Male sterilisation operation NOS |
Male sterilization (procedure) |
Male sterilisation reversal NOS |
Reversal of vasectomy |
Male sterilization operation NOS |
Male sterilization (procedure) |
refertilisation hos mand, ikke nærmere specificeret |
Reversal of vasectomy |
maleinsyreanhydridspecifikt ekstrakt |
Maleic anhydride |